PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33984694-0	2021	PARP inhibitor olaparib has a potential to increase the effectiveness of electrochemotherapy in BRCA1 mutated breast cancer in mice.	olaparib	15-23	breast cancer 1, early onset	Mus musculus	96-101	
32444694-2	2020	Olaparib inhibits PARP1/2 enzymatic activity and traps PARP1 on DNA at single-strand breaks, leading to replication-induced DNA damage that requires BRCA1/2-dependent homologous recombination repair.	olaparib	0-8	breast cancer 1, early onset	Mus musculus	149-156	
32604417-7	2020	Olaparib is a PARP1/2 inhibitor recently FDA-approved for treatment of BRCA1 and BRCA2 mutation carriers with metastatic breast cancer.	olaparib	0-8	breast cancer 1, early onset	Mus musculus	71-76	
32546644-5	2020	EXPERIMENTAL DESIGN: 238 BRCA1 VUS - comprising most BRCA1 VUS known in the Netherlands and Belgium - were tested for their ability to complement Brca1 deficient mouse ES cells in HRR, using cisplatin and olaparib sensitivity assays and a DR-GFP HRR assay.	olaparib	205-213	breast cancer 1, early onset	Mus musculus	25-30	
32134529-0	2020	Olaparib and enzalutamide synergistically suppress HCC progression via the AR-mediated miR-146a-5p/BRCA1 signaling.	olaparib	0-8	breast cancer 1, early onset	Mus musculus	99-104	
32368391-6	2020	We demonstrated that CDKI-73 could downregulate BRCA1 expression, resulting in hypersensitivity to olaparib in BRCA1-proficient ovarian cancer.	olaparib	99-107	breast cancer 1, early onset	Mus musculus	48-53	
32134529-3	2020	Here, we found that olaparib, a FDA-approved PARP inhibitor, could enhance the cytotoxicity in HCC cells with a lower BRCA1 expression, and suppressing the AR with either Enz or AR-shRNA could further increase the olaparib sensitivity to better suppress the HCC cell growth via a synergistic mechanism that may involve suppressing the expression of BRCA1 and other DNA damage response (DDR) genes.	olaparib	20-28	breast cancer 1, early onset	Mus musculus	118-123	
32134529-3	2020	Here, we found that olaparib, a FDA-approved PARP inhibitor, could enhance the cytotoxicity in HCC cells with a lower BRCA1 expression, and suppressing the AR with either Enz or AR-shRNA could further increase the olaparib sensitivity to better suppress the HCC cell growth via a synergistic mechanism that may involve suppressing the expression of BRCA1 and other DNA damage response (DDR) genes.	olaparib	20-28	breast cancer 1, early onset	Mus musculus	349-354	
32218813-10	2020	Consequently, the combination of pharmacological ascorbate and olaparib potently enhanced DNA DSBs and significantly decreased tumor burden, ascites volume and the number of tumor cells in ascites in mice bearing BRCA1/2 wild-type ovarian cancer xenografts.	olaparib	63-71	breast cancer 1, early onset	Mus musculus	213-220	
30414739-4	2019	METHODS: BRCA1 wildtype ovarian cancer cells (A2780 and SKOV3) were treated with a combination of CCND1 siRNA and olaparib in vitro.	olaparib	114-122	breast cancer 1, early onset	Mus musculus	9-14	
30025822-0	2018	Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas.	olaparib	41-49	breast cancer 1, early onset	Mus musculus	53-58	
30025822-6	2018	RESULTS: BRCA1-deficient HGSOC cells were more sensitive to RT alone and exhibited significantly higher levels of olaparib-mediated radiosensitization compared to BRCA1-proficient cells.	olaparib	114-122	breast cancer 1, early onset	Mus musculus	9-14	
30025822-8	2018	The growth-inhibitory effects of the combined olaparib and RT treatment were more pronounced in mice bearing BRCA1-deficient tumors compared to BRCA1-proficient tumors.	olaparib	46-54	breast cancer 1, early onset	Mus musculus	109-114	
28069724-5	2017	A combination of IMMU-132 plus olaparib or talazoparib produces significantly improved antitumor effects and delay in time-to-tumor progression compared with monotherapy in mice bearing BRCA1/2-mutated HCC1806 TNBC tumors.	olaparib	31-39	breast cancer 1, early onset	Mus musculus	186-191	
28069724-6	2017	Furthermore, in mice bearing BRCA1/2-wild-type tumors (MDA-MB-468 or MDA-MB-231), the combination of IMMU-132 plus olaparib imparts a significant antitumor effect and survival benefit above that achieved with monotherapy.	olaparib	115-123	breast cancer 1, early onset	Mus musculus	29-34	
27498558-1	2016	Poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) olaparib has been approved for treatment of advanced ovarian cancer associated with BRCA1 and BRCA2 mutations.	olaparib	54-62	breast cancer 1, early onset	Mus musculus	138-143	
27943283-9	2017	Prophylactic therapy with olaparib significantly prolonged mammary tumour-free survival without any significant increase in the fraction of BRCA1-proficient tumours, warranting the evaluation of this PARP inhibitor in prophylactic trials in BRCA1-mutation carriers.	olaparib	26-34	breast cancer 1, early onset	Mus musculus	241-246	
34504648-8	2021	This effect was enhanced following treatment of the cells with the combination of selinexor and olaparib, which showed synergistic effects on tumor growth inhibition in MDA-MB-468-derived (BRCA1-wt) and MDA-MB-436-derived (BRCA1-mut) xenografts.	olaparib	96-104	breast cancer 1, early onset	Mus musculus	189-194	
33767581-6	2021	We further demonstrated that combined treatment of Brca1-mutant mammary tumors with irradiation and AZD2281, which inhibits PARP, significantly reduced tumor progression and extended survival.	olaparib	100-107	breast cancer 1, early onset	Mus musculus	51-56	
27323902-2	2016	When combining the PARP1 inhibitor olaparib with cisplatin in a BRCA1-mutated breast cancer mouse model, the combination induced a larger response than either of the two compounds alone.	olaparib	35-43	breast cancer 1, early onset	Mus musculus	64-69	
22759740-5	2012	Additionally, olaparib has been reported to augment the effects of cisplatin and carboplatin on recurrence-free survival and OS in mice bearing BRCA1/2-deficient tumors.Given that hereditary EOC with deleterious BRCA1/2 mutations and BRCAness sporadic EOC are profoundly susceptible to synthetic lethality with PARP inhibition, it is imperative to identify a population of EOC patients that is likely to respond to PARP inhibitors.	olaparib	14-22	breast cancer 1, early onset	Mus musculus	144-149	
34126369-0	2021	Corrigendum to "PARP inhibitor olaparib has a potential to increase the effectiveness of electrochemotherapy in BRCA1 mutated breast cancer in mice" (Bioelectrochemistry 2021 (140) 107832).	olaparib	31-39	breast cancer 1, early onset	Mus musculus	112-117	
34504648-8	2021	This effect was enhanced following treatment of the cells with the combination of selinexor and olaparib, which showed synergistic effects on tumor growth inhibition in MDA-MB-468-derived (BRCA1-wt) and MDA-MB-436-derived (BRCA1-mut) xenografts.	olaparib	96-104	breast cancer 1, early onset	Mus musculus	223-228	
35406579-0	2022	Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells.	olaparib	51-59	breast cancer 1, early onset	Mus musculus	93-98	
35406579-0	2022	Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells.	olaparib	74-82	breast cancer 1, early onset	Mus musculus	93-98	
35406579-3	2022	METHODS: ID8 F3 (HR proficient) and ID8 Brca1-/- (HR deficient) murine ovarian cells resistant to olaparib, a PARPi, were generated through stepwise drug concentrations in vitro.	olaparib	98-106	breast cancer 1, early onset	Mus musculus	40-45	
35406579-5	2022	RESULTS: In ID8, cells with a HR proficient background, olaparib resistance was mainly caused by overexpression of multidrug resistance 1 gene (MDR1), while multiple heterogeneous co-existing mechanisms were found in ID8 Brca1-/- HR-deficient cells resistant to olaparib, including overexpression of MDR1, a decrease in PARP1 protein level and partial reactivation of HR repair.	olaparib	56-64	breast cancer 1, early onset	Mus musculus	221-226